Soleus Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Soleus Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-45,500	Closed	-$872K	–	95
2024 Q4	$872K	Sell	45,500 -49,500	-52%	-$1.08M	0.05%	75
2024 Q3	$2.16M	Sell	95,000 -245,000	-72%	-$4.01M	0.17%	77
2024 Q2	$4.42M	Hold	340,000	–	–	0.39%	65
2024 Q1	$5.95M	Buy	340,000 +202,000	+146%	+$3.92M	0.44%	61
2023 Q4	$3.01M	Buy	+138,000	New	+$2.18M	0.33%	49
2023 Q3	–	Sell	-34,000	Closed	-$809K	–	116
2023 Q2	$809K	Buy	+34,000	New	+$872K	0.09%	87
2022 Q4	–	Sell	-19,518	Closed	-$400K	–	91
2022 Q3	$400K	Sell	19,518 -821,500	-98%	-$14.8M	0.05%	76
2022 Q2	$9.73M	Buy	841,018 +751,018	+834%	+$10.1M	1.52%	22
2022 Q1	$1.66M	Hold	90,000	–	–	0.21%	59
2021 Q4	$1.78M	Buy	+90,000	New	+$1.68M	0.18%	54
2021 Q2	–	Sell	-67,685	Closed	-$1.13M	–	77
2021 Q1	$1.13M	Sell	67,685 -13,500	-17%	-$253K	0.2%	63
2020 Q4	$1.33M	Buy	+81,185	New	+$1.22M	0.18%	48

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Soleus Capital Management's VRDN Position: Q1 2025 in Review

Soleus Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 45,500 shares — an estimated $872K sold.

Soleus Capital Management first reported a position in VRDN in Q4 2020 and held it in 12 quarters. The position peaked at $9.73M in Q2 2022. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

Soleus Capital Management reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
Soleus Capital Management sold 45,500 Viridian Therapeutics shares in Q1 2025, an estimated $872K.
Soleus Capital Management first reported a position in Viridian Therapeutics in Q4 2020 and held it in 12 quarters.
Soleus Capital Management's Viridian Therapeutics position peaked at $9.73M in Q2 2022.
176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.